W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS…
Miasta: Bystra, Gdańsk, Kielce, Olsztyn i 2 inne miastaWiek: od 18 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza III
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic…
Miasta: Katowice, Kielce, Kraków, Lublin i 5 innych miastWiek: od 18 latSponsor: Pfizer Inc.
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Miasta: Gliwice, Kielce, Olsztyn, Otwock i 5 innych miastWiek: od 18 latSponsor: Glaxosmithkline Research & Development Limited
RekrutujeFaza III
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Miasta: Kielce, Lublin, Olsztyn, Otwock i 6 innych miastWiek: od 18 latSponsor: Maia Biotechnology Inc.
RekrutujeFaza III
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Miasta: Kielce, Poznań, SzczecinWiek: od 18 latSponsor: Eli Lilly and Company
RekrutujeFaza I/II
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With…
Miasta: Białystok, Bydgoszcz, Gdańsk, Kielce i 2 inne miastaWiek: od 18 latSponsor: AbbVie Deutschland GmbH & Co. KG
RekrutujeFaza II/III
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Miasta: Białystok, Bydgoszcz, Gdańsk, Gliwice i 11 innych miastWiek: od 18 latSponsor: BioNTech SE
RekrutujeFaza III
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Miasta: Gdańsk, Kielce, Kraków, Olsztyn i 4 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC)…
Miasta: Białystok, Kielce, Otwock, Poznań i 3 inne miastaWiek: od 18 latSponsor: Bayer AG
RekrutujeFaza III
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Miasta: Kielce, Szczecin, ToruńWiek: od 18 latSponsor: Eli Lilly & Co.
RekrutujeFaza II/III
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Miasta: Gdańsk, Kielce, Kraków, Lublin i 6 innych miastWiek: od 18 latSponsor: Mirati Therapeutics Inc.